ET8 Stock Overview
A specialty biopharmaceutical company, engages in developing and commercializing therapeutics and diagnostic tests in Canada, Switzerland, Ireland, Denmark, Germany, the United States, and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
COSCIENS Biopharma Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$5.30 |
| 52 Week High | CA$10.14 |
| 52 Week Low | CA$3.91 |
| Beta | 2.26 |
| 11 Month Change | -0.75% |
| 3 Month Change | -32.05% |
| 1 Year Change | -47.52% |
| 33 Year Change | -89.51% |
| 5 Year Change | -97.11% |
| Change since IPO | -99.99% |
Recent News & Updates
Recent updates
Shareholder Returns
| ET8 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 12.1% | 2.6% | 2.7% |
| 1Y | -47.5% | -21.9% | 2.9% |
Return vs Industry: ET8 underperformed the German Biotechs industry which returned -21.9% over the past year.
Return vs Market: ET8 underperformed the German Market which returned 2.9% over the past year.
Price Volatility
| ET8 volatility | |
|---|---|
| ET8 Average Weekly Movement | 17.4% |
| Biotechs Industry Average Movement | 6.2% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.8% |
| 10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: ET8's share price has been volatile over the past 3 months.
Volatility Over Time: ET8's weekly volatility has increased from 12% to 17% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1990 | n/a | Gilles Gagnon | www.cosciensbio.com |
COSCIENS Biopharma Inc., a specialty biopharmaceutical company, engages in developing and commercializing therapeutics and diagnostic tests in Canada, Switzerland, Ireland, Denmark, Germany, the United States, and internationally. Its lead product is Macrilen (macimorelin), an orally available peptidomimetic ghrelin receptor (GHSR-1a) agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a for the diagnosis of patients with adult growth hormone deficiency and childhood-onset growth hormone deficiency, as well as endocrinology and oncology indications; AEZS-150, a delayed clearance parathyroid hormone fusion polypeptide that is in preclinical trial for the treatment of chronic hypoparathyroidism; and AEZS-130 that is in preclinical trial for the treatment of amyotrophic lateral sclerosis. The company also has a license and research agreement with University of Wuerzburg to develop, manufacture, and commercialize AIM biologicals for the treatment of neuromyelitis optica spectrum disorder; and for pre-clinical development towards the potential treatment of Parkinson’s disease.
COSCIENS Biopharma Inc. Fundamentals Summary
| ET8 fundamental statistics | |
|---|---|
| Market cap | €17.15m |
| Earnings (TTM) | -€16.54m |
| Revenue (TTM) | €4.46m |
4.0x
P/S Ratio-1.1x
P/E RatioIs ET8 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ET8 income statement (TTM) | |
|---|---|
| Revenue | US$4.92m |
| Cost of Revenue | US$901.00k |
| Gross Profit | US$4.01m |
| Other Expenses | US$22.24m |
| Earnings | -US$18.23m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -5.85 |
| Gross Margin | 81.67% |
| Net Profit Margin | -370.91% |
| Debt/Equity Ratio | 0% |
How did ET8 perform over the long term?
See historical performance and comparison